- Home
- THRD
as 07-26-2024 4:00pm EST
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 532.3M | IPO Year: | 2022 |
| Target Price: | $16.00 | AVG Volume (30 days): | 102.8K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.41 - $16.94 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Third Harmonic Bio Inc. (THRD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Person Julie | THRD | CHIEF ADMINISTRATIVE OFFICER | Jun 26 '24 | Sell | $12.46 | 10,000 | $124,569.00 | 0 | SEC Form 4 |
| Dittman Jennifer | THRD | Chief Development Oper Officer | Jun 7 '24 | Sell | $14.17 | 494 | $6,999.98 | 0 | SEC Form 4 |
| Dittman Jennifer | THRD | Chief Development Oper Officer | May 20 '24 | Sell | $14.00 | 1,042 | $14,588.00 | 0 | SEC Form 4 |
| Dittman Jennifer | THRD | Chief Development Oper Officer | May 16 '24 | Sell | $14.04 | 23,578 | $331,065.77 | 0 | SEC Form 4 |
| Holles Natalie C. | THRD | CEO | May 9 '24 | Sell | $12.18 | 20,222 | $246,299.92 | 1,218,836 | SEC Form 4 |
| Holles Natalie C. | THRD | CEO | Apr 11 '24 | Sell | $12.19 | 13,558 | $165,213.72 | 1,218,836 | SEC Form 4 |
| Person Julie | THRD | CHIEF ADMINISTRATIVE OFFICER | Apr 4 '24 | Sell | $10.00 | 1,107 | $11,070.00 | 0 | SEC Form 4 |
| Person Julie | THRD | Chief Administrative Officer | Dec 5 '23 | Sell | $10.30 | 12,863 | $132,483.75 | 0 | SEC Form 4 |
| Conner Edward R. | THRD | Chief Medical Officer | Dec 5 '23 | Sell | $10.03 | 4,790 | $48,062.38 | 0 | SEC Form 4 |
Latest Third Harmonic Bio Inc. News
THRD Breaking Stock News: Dive into THRD Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
MT Newswires
2 months ago
Third Harmonic Bio Insider Sold Shares Worth $331,066, According to a Recent SEC Filing
GlobeNewswire
2 months ago
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
Zacks
2 months ago
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
GuruFocus.com
3 months ago
Insider Sale: CEO Natalie Holles Sells Shares of Third Harmonic Bio Inc (THRD)
GuruFocus.com
3 months ago
Third Harmonic Bio Inc CEO Natalie Holles Sells 13,558 Shares
Simply Wall St.
4 months ago
We're Not Worried About Third Harmonic Bio's (NASDAQ:THRD) Cash Burn
GlobeNewswire
4 months ago
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
Compare THRD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "THRD Third Harmonic Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.